J&J, AbbVie cancer drug significantly slows progression of rare lymphoma: study
By Michael Erman (Reuters) – Johnson & Johnson and AbbVie’s big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two…
J&J tried to get federal judge to block publication of Reuters story
By Maria Chutchian and Tom Hals – Johnson & Johnson tried to get a U.S. judge to block Reuters from publishing a story based on what it said were confidential company documents…
Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO
– Belgian drugmaker Galapagos NV on Wednesday named former Johnson & Johnson senior executive Paul Stoffels as its chief executive officer, effective April 1. Stoffels was the chief scientific officer of Johnson…
Breaking News
